SFE Investment Counsel Sells 19,266 Shares of Zoetis Inc. $ZTS

SFE Investment Counsel lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 80.7% in the 2nd quarter, Holdings Channel reports. The firm owned 4,615 shares of the company’s stock after selling 19,266 shares during the quarter. SFE Investment Counsel’s holdings in Zoetis were worth $332,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. J. Stern & Co. LLP increased its position in Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after buying an additional 23,877,416 shares during the last quarter. Norges Bank acquired a new stake in shares of Zoetis in the fourth quarter worth about $734,425,000. Vanguard Group Inc. boosted its stake in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. bought a new stake in shares of Zoetis during the 1st quarter worth about $286,660,000. Finally, Van ECK Associates Corp increased its holdings in shares of Zoetis by 269.0% during the 4th quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock valued at $300,340,000 after acquiring an additional 1,740,113 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent analyst reports. Citigroup cut their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. JPMorgan Chase & Co. lowered their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Piper Sandler dropped their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, August 10th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $109.62.

Zoetis Stock Down 2.9%

Shares of ZTS opened at $73.64 on Friday. The company has a 50-day simple moving average of $76.30 and a 200-day simple moving average of $99.01. The firm has a market capitalization of $30.43 billion, a P/E ratio of 12.13, a P/E/G ratio of 1.28 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a 52 week low of $71.45 and a 52 week high of $160.48.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the company earned $1.76 earnings per share. The firm’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s dividend payout ratio (DPR) is currently 34.93%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.